Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Castro

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2000
Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expressionC Guillot, P Mathieu, H Coathalem, et al.
Human Gene Therapy|May 24, 2006
Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reactionM Puntel, J F Curtin, J M Zirger, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomasS Windeatt, T D Southgate, R A Dewey, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2005
Regulatable gene expression systems for gene therapy applications: progress and future challengesS Goverdhana, M Puntel, W Xiong, et al.
Journal of Virology|December 17, 2008
Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivoM Puntel, R J Barrett, S Mondkar, et al.
Revue Scientifique Et Technique (International Office of Epizootics)|March 23, 2012
First detection of the equine herpesvirus 1 neuropathogenic variant in BrazilE Mori, A S Borges, D J Z Delfiol, et al.
Clinical Pharmacology and Therapeutics|February 19, 2010
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastomaA K M G Muhammad, M Puntel, M Candolfi, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
Journal of Immunology (Baltimore, Md. : 1950)|May 9, 2000
Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expressionC Guillot, P Mathieu, H Coathalem, et al.
Human Gene Therapy|May 24, 2006
Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reactionM Puntel, J F Curtin, J M Zirger, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2000
Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomasS Windeatt, T D Southgate, R A Dewey, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2005
Regulatable gene expression systems for gene therapy applications: progress and future challengesS Goverdhana, M Puntel, W Xiong, et al.
Journal of Virology|December 17, 2008
Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivoM Puntel, R J Barrett, S Mondkar, et al.
Revue Scientifique Et Technique (International Office of Epizootics)|March 23, 2012
First detection of the equine herpesvirus 1 neuropathogenic variant in BrazilE Mori, A S Borges, D J Z Delfiol, et al.
Clinical Pharmacology and Therapeutics|February 19, 2010
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastomaA K M G Muhammad, M Puntel, M Candolfi, et al.
Pageof 16